A high-activity UK & EU sector, led by NHS ENGLAND, most recent listing 11 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Tramadol and Paracetamol, in accordance with German social law. The contracts will be valid from October 1, 2025, to September 30, 2027, and suppliers can enter into contracts at
This contract opportunity involves the establishment of non-exclusive discount contracts for medications containing the active ingredients Olodaterol and Tiotropium Bromide. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the possibility of entering into contracts a
The Kaufmännische Krankenkasse (KKH) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under Section 130a, Paragraph 8 of the Social Code Book V (SGB V) through an 'Open-House' procedure. This process allows all eligible and interes
The KKH (Kaufmännische Krankenkasse) is seeking to establish non-exclusive discount agreements with pharmaceutical companies for specific active ingredients under the Open-House procedure. This opportunity is open to all qualified pharmaceutical companies or groups of companies interested in enterin
The health insurance funds (whether HEK and/or hkk participate in each lot is determined by the designation of the respective lot) aim to establish discount contracts with all suitable pharmaceutical companies according to § 130a Abs. 8 SGB V for the active ingredients, combinations of active ingred
This contract opportunity involves establishing a non-exclusive discount agreement for the medication Omalizumab (ATC Code: R03DX05) in Germany. The contract will be effective from December 1, 2024, to November 30, 2026, with the option for suppliers to enter into the contract at any time during thi
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abrocitinib (ATC D11AH08) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will involve formal procurement proced
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication containing the active ingredients Tafluprost and Timolol (ATC S01ED70). This agreement is in accordance with § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical com
The DAK-Gesundheit is seeking pharmaceutical companies to enter into a non-exclusive discount agreement for the drug Umeclidinium (ATC R03BB07) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will follow the formal
AOK Bayern is seeking pharmaceutical companies to enter into non-exclusive discount agreements for the drug Airpiprazol in the form of depot injection suspension (ATC N05AX12). This is not a traditional open procedure but an open-house model, meaning contracts can be signed at any time until July 3,
